# The MW Cancer Prevention Clinical Trials Network

> **NIH NIH UG1** · UNIVERSITY OF WISCONSIN-MADISON · 2024 · $1,552,933

## Abstract

ABSTRACT
The need to provide safe and cost-effective measures to prevent Cancer is self-explanatory. The University of
Wisconsin (UWISC) as the Lead Academic Organization (LAO) together with our collaborating institutions
(Affiliated Organizations/AOs) propose to continue performing early phase cancer prevention trials, for the
National Cancer Institute (NCI), Division of Cancer Prevention (DCP), as a Cancer Prevention Clinical Trials
Network (CP-CTNET) site funded as a UG1 Consortium as described in RFA-CA-18-031. Our overarching goal
is to evaluate the effects of novel preventive agents/interventions on pertinent biological endpoints in order to
efficiently determine their appropriateness for further testing and potential viability toward becoming
recommended societal interventions to lessen the burden of cancer. We will pursue this overarching goal via
the following specific aims: (1) Efficiently design, conduct and perform Phase 0, 1, 2 Chemoprevention Clinical
Trials of novel and/or re-purposed immunologic-based or molecular targeted agents, assessing their effects upon
relevant biological (biomarkers/clinical effects) endpoints. (2) Build upon existing consortium infrastructure to
complete Aim 1 via intra- or inter-consortium (CP-CTNET) multi-institutional collaborations in concert with
NCI/DCP contributing three to four new Phase 0, 1 or 2 clinical trials and accrual of ≥ 40-50 subjects per year.
We are well positioned to successfully achieve the above aims due to our combined experience with prevention
agent development (consortium members currently hold >90 DCP sponsored R, U or PREVENT awards) and
our consortium's staffing, organization, and management which results in the timely development, performance
and completion of impactful, multi-institutional early phase cancer prevention trials. Our enhanced consortium
consists of >10 NCI-designated Cancer Centers, institutions providing access to robust numbers of at-risk
patients (e.g. Mayo Clinics, Seattle Cancer Care Alliance) and expanded access to at-risk under-represented
minorities and special populations (e.g. University of Puerto Rico, Alaska Native Medical Center). Supported by
the Carbone Cancer Center, the University of Wisconsin CP-CTNet site is determined to contribute to advancing
the field of Cancer prevention through performance of early phase prevention trials.

## Key facts

- **NIH application ID:** 10908588
- **Project number:** 5UG1CA242635-05
- **Recipient organization:** UNIVERSITY OF WISCONSIN-MADISON
- **Principal Investigator:** Lisa M Barroilhet
- **Activity code:** UG1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $1,552,933
- **Award type:** 5
- **Project period:** 2020-09-03 → 2026-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10908588

## Citation

> US National Institutes of Health, RePORTER application 10908588, The MW Cancer Prevention Clinical Trials Network (5UG1CA242635-05). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10908588. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*